Zobrazeno 1 - 10
of 36
pro vyhledávání: '"33"'
Autor:
Jonas Bergh, Markella Zacharouli, Ioannis Zerdes, Johan Hartman, Luuk Harbers, Michele Simonetti, Susanne Agartz, Ning Zhang, Dimitrios Salgkamis, Alexios Matikas, Theodoros Foukakis, Nicola Crosetto, Pablo Moreno-Ruiz, Artur Mezheyeuski
Publikováno v:
Cancer Research. 81:PS18-27
Background: Given the emerging role of immune-related biomarkers in breast cancer (BC), little is known about specific immune cell composition patterns and genomic alterations and how these could interact in early BC setting. The aim of this proof-of
Autor:
Wytske M. van Weerden, Ronald de Wit, Ron H.J. Mathijssen, Erik A.C. Wiemer, Ellen S. de Morree, Herman Burger, Corrina M.A. de Ridder
Publikováno v:
Cancer Research. 73:316-316
Introduction: The first line of chemotherapy for castration resistant prostate cancer (CRPC) patients is docetaxel treatment. Continued treatment after progression on docetaxel with cabazitaxel can be very strenuous for patients. Clearly, selection o
Autor:
K Kaneko, Nayuko Sato, Noriyuki Masuda, Chizuko Kanbayashi, M. Toi, Hiroyuki Yasojima, Shigetoyo Saji, Takashi Morimoto, Taro Ueno, Shinji Ohno, Hironobu Sasano, Satoshi Morita
Publikováno v:
Cancer Research. 79:P4-14
Aim To investigate the efficacy and safety of initial neoadjuvant endocrine therapy with exemestane (EXE) alone followed by tailored treatment: continued EXE monotherapy for responders or EXE plus docetaxel–cyclophosphamide (TC) combination therapy
Autor:
Matthew J. Ellis, Jo Anne Zujewski, Monica M. Mita, J. M. Guenther, Wajeeha Razaq, Anna Weiss, Kelly K. Hunt, T Dockter, Cynthia X. Ma, Olwen Hahn, Lisa A. Carey, Mark A. Watson, S Sanati, Horacio Maluf, Vera J. Suman, Yang Wang, Jeremy Hoog, Kiran Vij, Clifford A. Hudis, Gary Unzeitig, Tina J. Hieken, Amy Tiersten, Eric P. Winer, Ann H. Partridge, Erika C. Crouch, A. Marilyn Leitch, Abigail S. Caudle
Publikováno v:
Cancer Research. 81:GS4-05
Background: Ki67 values >10% 2-4 weeks (wks) after starting neoadjuvant ET (NET) indicates persistent cell proliferation, resistance to ET, and is associated with increased risk of recurrence. The ACOSOG Z1031 trial suggested that these tumors are al
Publikováno v:
Cancer Research. 78:P6-11
Background Chemotherapy-induced alopecia (CIA) is able to affect a patient's self-image and confidence negatively. A decade ago scalp cooling failed to avoid chemotherapy- induced hairloss in women who underwent chemotherapy as only thermal packs wer
Autor:
Jane Beith, R H de Boer, W Roberts, Michelle White, M Truman, Andrew Redfern, Natasha Woodward
Publikováno v:
Cancer Research. 77:P4-21
Background: Pertuzumab targets the human epidermal growth factor receptor 2 (HER2) through an independent epitope to that of trastuzumab. Improved efficacy with acceptable toxicity has been shown, in metastatic breast cancer (mBC) for pertuzumab in c
Publikováno v:
Cancer Research. 76:P4-14
Introduction: In the CLEOPATRA study, pertuzumab (P) plus trastuzumab (T) and docetaxel (D) significantly improved median progression-free survival (PFS) and overall survival (OS) compared with placebo (Pla) plus T and D in pts with HER2-positive met
Autor:
Michael F. Press, Rodrigo Fresco, John R. Mackey, K Gelmon, Graham Lawrence Cohen, J García-Saenz, S Morales-Murillo, Vincent Houe, Guy Jerusalem, Mahalakshmi Kumaran, I Kiselev, Francois Thireau, J-L Canon, Vera Gorbunova, Dany Abigerges, Sambasivarao Damaraju
Publikováno v:
Cancer Research. 76:P1-13
Background: Genetic predisposition to docetaxel (Doc) toxicity contributes to unacceptable toxicity and reduced dose intensity, and may influence disease outcomes. We previously reported variants associated with Doc toxicity in candidate gene single
Publikováno v:
Cancer Research. 76:P1-10
Background Metabolic syndrome is associated with various malignancies, including breast cancer. Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome. NAFLD is frequently observed during chemotherapy, but its clin
Autor:
G-Y Gong, Kyung Hae Jung, J-H Ahn, HJ Lee, E-M Lee, B-H Son, J.K. Kim, Soohyoun Ahn, H-H Kim, S-B Kim, Hee Jung Shin, EJ Ha, S-H Ahn
Publikováno v:
Cancer Research. 76:P1-14
Background: The addition of a taxane to anthracycline-based chemotherapy provided an improved outcome in neoadjuant setting. Two neoadjuvant chemotherapy with 4 cycles of AC followed by 4 cycles of docetaxel (AC4-D4) and 3 cycles of FEC followed by 3